Parkman Healthcare Partners LLC Reduces Stock Position in NewAmsterdam Pharma (NASDAQ:NAMS)

Parkman Healthcare Partners LLC decreased its position in NewAmsterdam Pharma (NASDAQ:NAMS - Free Report) by 27.7% during the 4th quarter, according to its most recent filing with the SEC. The institutional investor owned 76,116 shares of the company's stock after selling 29,218 shares during the period. Parkman Healthcare Partners LLC owned about 0.08% of NewAmsterdam Pharma worth $1,956,000 as of its most recent filing with the SEC.

Several other institutional investors have also recently bought and sold shares of NAMS. Bain Capital Life Sciences Investors LLC raised its stake in NewAmsterdam Pharma by 2.3% in the 4th quarter. Bain Capital Life Sciences Investors LLC now owns 10,719,110 shares of the company's stock valued at $275,481,000 after acquiring an additional 245,197 shares during the period. RA Capital Management L.P. increased its position in shares of NewAmsterdam Pharma by 9.7% in the fourth quarter. RA Capital Management L.P. now owns 8,845,000 shares of the company's stock worth $227,316,000 after purchasing an additional 781,000 shares during the period. Deerfield Management Company L.P. Series C increased its position in shares of NewAmsterdam Pharma by 378.4% in the fourth quarter. Deerfield Management Company L.P. Series C now owns 4,314,340 shares of the company's stock worth $110,879,000 after purchasing an additional 3,412,590 shares during the period. Jennison Associates LLC increased its position in shares of NewAmsterdam Pharma by 291.9% in the fourth quarter. Jennison Associates LLC now owns 3,998,541 shares of the company's stock worth $102,763,000 after purchasing an additional 2,978,263 shares during the period. Finally, Wellington Management Group LLP increased its position in shares of NewAmsterdam Pharma by 2,410.4% in the fourth quarter. Wellington Management Group LLP now owns 2,315,123 shares of the company's stock worth $59,499,000 after purchasing an additional 2,222,900 shares during the period. Institutional investors own 89.89% of the company's stock.

Insider Transactions at NewAmsterdam Pharma

In other NewAmsterdam Pharma news, CAO Louise Frederika Kooij sold 150,000 shares of the business's stock in a transaction that occurred on Tuesday, March 4th. The stock was sold at an average price of $20.37, for a total value of $3,055,500.00. Following the completion of the sale, the chief accounting officer now owns 15,000 shares in the company, valued at approximately $305,550. The trade was a 90.91% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, Director James N. Topper acquired 4,005 shares of the stock in a transaction dated Tuesday, March 4th. The shares were purchased at an average cost of $21.02 per share, with a total value of $84,185.10. Following the completion of the purchase, the director now owns 3,012,434 shares of the company's stock, valued at approximately $63,321,362.68. The trade was a 0.13% increase in their position. The disclosure for this purchase can be found here. Insiders own 20.84% of the company's stock.

NewAmsterdam Pharma Stock Performance

NewAmsterdam Pharma stock traded up $0.13 during mid-day trading on Monday, reaching $19.01. The company's stock had a trading volume of 321,868 shares, compared to its average volume of 631,181. The firm's fifty day moving average price is $19.08 and its two-hundred day moving average price is $21.27. NewAmsterdam Pharma has a 12-month low of $14.06 and a 12-month high of $27.29. The company has a market capitalization of $2.09 billion, a P/E ratio of -10.11 and a beta of 0.01.

NewAmsterdam Pharma (NASDAQ:NAMS - Get Free Report) last posted its earnings results on Thursday, May 8th. The company reported ($0.49) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.45) by ($0.04). The business had revenue of $2.98 million for the quarter, compared to analyst estimates of $1.46 million. On average, research analysts predict that NewAmsterdam Pharma will post -1.75 EPS for the current fiscal year.

Analysts Set New Price Targets

NAMS has been the topic of a number of recent analyst reports. UBS Group set a $41.00 target price on NewAmsterdam Pharma in a research report on Monday, March 3rd. Royal Bank of Canada reissued an "outperform" rating and issued a $40.00 price target on shares of NewAmsterdam Pharma in a research note on Friday, January 24th. Needham & Company LLC lowered their target price on NewAmsterdam Pharma from $42.00 to $40.00 and set a "buy" rating on the stock in a research report on Thursday, May 8th. Finally, Scotiabank upped their target price on NewAmsterdam Pharma from $47.00 to $52.00 and gave the stock a "sector outperform" rating in a research report on Thursday, February 27th. Five analysts have rated the stock with a buy rating, According to MarketBeat, the stock has an average rating of "Buy" and a consensus price target of $43.00.

NewAmsterdam Pharma Profile

NewAmsterdam Pharma Company N.V., a late-stage biopharmaceutical company, develops therapies to enhance patient care in populations with metabolic disease. It is developing obicetrapib, an oral low-dose cholesteryl ester transfer protein (CETP) inhibitor, that is in various clinical trials as a monotherapy and a combination therapy with ezetimibe for lowering LDL-C for cardiovascular diseases.